Therapeutic Application of Synthetic HDL for Treatment of Autoimmune Diseases
James Moon, Pharmacy; Anna Schwendeman, Pharmacy; Mariana Kaplan, Medicine

Autoimmune diseases such as systemic lupus eritematosus (SLE) and rheumatoid arthritis (RA) had been associated with increased risk of cardiovascular diseases. Both diseases are characterized by decreased levels of high density lipoprotein (HDL), which is a nanoparticle composed of Apoliporotein A-I (ApoA-I) and phospholipids that carries a number of signaling lipid molecules such as sphingosine-1-phoshate (S1P). HDL also exhibits anti-oxidant and anti-inflammatory properties. In this project we will explore if infusions of synthetic HDL nanoparticles with or without incorporated S1P could be a beneficial therapeutic intervention for the treatment of autoimmune diseases in murine models. We will also examine the potential mechanisms of the therapeutics benefits by measuring the levels of circulating antibodies, cytokines, and examining pathological changes/organ damage. 

Listing Row

Monday, March 3, 2014
Monday, March 3, 2014